Jorge Rios, MD | Authors

CHASE DRUG

PO BOX 400

703 MAIN AVE

58577

Articles

PARP Inhibitors in Breast Cancer: BRCA and Beyond

October 15, 2011

The aim of this article is to review the preclinical data and rationale for PARP inhibitor use in the aforementioned settings, as well as the current status of the clinical development of these agents in the treatment of breast cancer, along with future directions for research in this field.